Standardized diagnosis and treatment of gallbladder cancer and advances in comprehensive therapy

doi:10.3877/cma.j.issn.2095-3232.2026.05.005

Abstract

Abstract:

Gallbladder cancer is a highly aggressive malignancy with a poor prognosis. Radical surgery is an important means of improving prognosis. However, because early-stage gallbladder cancer lacks specific symptoms, most patients have already lost the opportunity for radical surgery by the time of diagnosis. Standardized diagnosis and treatment can help patients achieve more possible therapeutic benefit. In recent years, rapid advances in targeted therapy and immunotherapy have provided new directions for the treatment of gallbladder cancer. This article aims to summarize the currently recommended standardized diagnostic and therapeutic approaches, as well as emerging targeted therapy and immunotherapy strategies.

Key words: Gallbladder cancer, Surgery, Comprehensive treatment, Targeted therapy, Immunotherapy

Kexian Li, Hao Qian, Xiaxing Deng. Standardized diagnosis and treatment of gallbladder cancer and advances in comprehensive therapy[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2026, 15(05): 711-717.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2026.05.005

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2026/V15/I05/711

References 59

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.DOI: 10.3322/caac.21492.
[2]	Roa JC, García P, Kapoor VK, et al. Gallbladder cancer[J]. Nat Rev Dis Primers, 2022, 8: 69.DOI: 10.1038/s41572-022-00398-y.
[3]	中华医学会外科学分会胆道外科学组, 中国医师协会外科医师分会胆道外科专业委员会. 胆囊癌诊断和治疗指南(2019版)[J]. 中华外科杂志, 2020, 58(4): 243-251.DOI: 10.3760/cma.j.cn112139-20200106-00014.
[4]	Lv TR, Wang JK, Li FY, et al. Prognostic factors for resected cases with gallbladder carcinoma: a systematic review and meta-analysis[J]. Int J Surg, 2024, 110(7): 4342-4355.DOI: 10.1097/js9.0000000000001403.
[5]	Kim SJ, Lee JM, Lee JY, et al. Accuracy of preoperative T-staging of gallbladder carcinoma using MDCT[J]. AJR Am J Roentgenol, 2008, 190(1): 74-80.DOI: 10.2214/ajr.07.2348.
[6]	Kumaran V, Gulati M, Paul S, et al. The role of dual-phase helical CT in assessing resectability of carcinoma of the gallbladder[J]. Eur Radiol, 2002, 12(8): 1993-1999.DOI: 10.1007/s00330-002-1440-0.
[7]	Lee SW, Kim HJ, Park JH, et al. Clinical usefulness of ¹⁸F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma[J]. J Gastroenterol, 2010, 45(5): 560-566.DOI: 10.1007/s00535-009-0188-6.
[8]	Ogura T, Kurisu Y, Masuda D, et al. Can endoscopic ultrasound-guided fine needle aspiration offer clinical benefit for thick-walled gallbladders[J]. Dig Dis Sci, 2014, 59(8): 1917-1924.DOI: 10.1007/s10620-014-3100-z.
[9]	Jang JY, Kim SW, Lee SE, et al. Differential diagnostic and staging accuracies of high resolution ultrasonography, endoscopic ultrasonography, and multidetector computed tomography for gallbladder polypoid lesions and gallbladder cancer[J]. Ann Surg, 2009, 250(6): 943-949.DOI: 10.1097/sla.0b013e3181b5d5fc.
[10]	杨智義, 赵成俊, 胡欣芫, 等. 外周血cfDNA液体活检技术在肝棘球蚴病诊治中的应用进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(3): 389-393.DOI: 10.3877/cma.j.issn.2095-3232.2024.03.022.
[11]	赵迪, 杨鑫鑫, 孟宏学. 液体活检技术在结直肠癌诊疗领域的应用[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(2): 135-140.DOI: 10.3877/cma.j.issn.2095-3224.2024.02.007.
[12]	Alix-Panabières C, Pantel K. Liquid biopsy: from discovery to clinical application[J]. Cancer Discov, 2021, 11(4): 858-873.DOI: 10.1158/2159-8290.cd-20-1311.
[13]	Hwang S, Woo S, Kang B, et al. Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer[J]. J Hepatol, 2025, 82(4): 649-657.DOI: 10.1016/j.jhep.2024.10.020.
[14]	Yang M, Zhao Y, Li C, et al. Multimodal integration of liquid biopsy and radiology for the noninvasive diagnosis of gallbladder cancer and benign disorders[J]. Cancer Cell, 2025, 43(3): 398-412. e4.DOI: 10.1016/j.ccell.2025.02.011.
[15]	Liu R, Wu S, Kuang T, et al. Prediction system for gallbladder cancer distant metastasis a retrospective cohort study based on machine learning[J]. Int J Surg, 2025, 111(11): 7906-7920.DOI: 10.1097/js9.0000000000002901.
[16]	Zhang K, He J, Ji W, et al. Machine learning model for differentiating xanthogranulomatous cholecystitis and gallbladder cancer in multicenter largescale study[J]. NPJ Digit Med, 2025, 8: 590.DOI: 10.1038/s41746-025-01991-7.
[17]	Wang LF, Wang Q, Mao F, et al. Risk stratification of gallbladder masses by machine learning-based ultrasound radiomics models: a prospective and multi-institutional study[J]. Eur Radiol, 2023, 33(12): 8899-8911.DOI: 10.1007/s00330-023-09891-8.
[18]	Lee SE. Systematic review on the surgical treatment for T1 gallbladder cancer[J]. World J Gastroenterol, 2011, 17(2): 174.DOI: 10.3748/wjg.v17.i2.174.
[19]	Palepu J, Endo I, Chaudhari VA, et al. 'IHPBA-APHPBA clinical practice guidelines': international Delphi consensus recommendations for gallbladder cancer[J]. HPB, 2024, 26(11): 1311-1326.DOI: 10.1016/j.hpb.2024.07.411.
[20]	中国抗癌协会. 中国恶性肿瘤整合诊治指南: 胆囊癌[J]. 肿瘤, 2022, 42(3): 188-202.DOI: 10.3781/j.issn.1000-7431.2022.2112-0938.
[21]	Kuipers H, de Savornin Lohman EAJ, van Dooren M, et al. Extended resections for advanced gallbladder cancer: results from a nationwide cohort study[J]. Ann Surg Oncol, 2021, 28(2): 835-843.DOI: 10.1245/s10434-020-08858-z.
[22]	Zhang K, Liu H, Zhao Y, et al. The clinical outcomes of extended resections in patients with Ⅳ stage gallbladder cancers: a retrospective study from a large tertiary center[J]. Front Oncol, 2022, 12: 1032737.DOI: 10.3389/fonc.2022.1032737.
[23]	Noji T, Takeuchi S, Wada M, et al. Short-and long-term surgical results of extended surgery for widespread gallbladder carcinoma[J]. In Vivo, 2025, 39(2): 1022-1032.DOI: 10.21873/invivo.13907.
[24]	Yamamoto Y, Sugiura T, Okamura Y, et al. Is combined pancreatoduodenectomy for advanced gallbladder cancer justified[J]. Surgery, 2016, 159(3): 810-820.DOI: 10.1016/j.surg.2015.09.009.
[25]	Basak F, Hasbahceci M, Canbak T, et al. Incidental findings during routine pathological evaluation of gallbladder specimens: review of 1,747 elective laparoscopic cholecystectomy cases[J]. Ann R Coll Surg Engl, 2016, 98(4): 280-283.DOI: 10.1308/rcsann.2016.0099.
[26]	Gani F, Buettner S, Margonis GA, et al. Assessing the impact of common bile duct resection in the surgical management of gallbladder cancer[J]. J Surg Oncol, 2016, 114(2): 176-180.DOI: 10.1002/jso.24283.
[27]	Du J, Yang XW, Wen ZJ, et al. Relationship between prognosis and time interval from cholecystectomy to reoperation in postoperative incidental gallbladder carcinoma[J]. Chin Med J, 2018, 131(20): 2503-2505.DOI: 10.4103/0366-6999.243565.
[28]	Sun J, Xie TG, Ma ZY, et al. Current status and progress in laparoscopic surgery for gallbladder carcinoma[J]. World J Gastroenterol, 2023, 29(16): 2369-2379.DOI: 10.3748/wjg.v29.i16.2369.
[29]	Chee MYM, Wu AGR, Fong KY, et al. Robotic, laparoscopic and open surgery for gallbladder cancer: a systematic review and network meta-analysis[J]. Surg Endosc, 2024, 38(9): 4846-4857.DOI: 10.1007/s00464-024-11162-6.
[30]	Jin LM, Zhang YH, Zhang CW, et al. Is laparoscopic radical cholecystectomy an effective and safe approach for advanced gallbladder cancer[J]. Hepatobiliary Pancreat Dis Int, 2020, 19(3): 203-204.DOI: 10.1016/j.hbpd.2020.04.005.
[31]	中华医学会外科学分会胆道外科学组, 中国医师协会外科医师分会胆道外科专家工作组. 腹腔镜胆囊癌根治性切除专家共识(2023)[J]. 中华外科杂志, 2024, 62(4): 265-272.DOI: 10.3760/cma.j.cn112139-20240129-00058.
[32]	Dong J, Zhu Z. Efficacy of neoadjuvant therapy and lymph node dissection in advanced gallbladder cancer without distant metastases: a SEER database analysis[J]. Front Oncol, 2024, 14: 1511583.DOI: 10.3389/fonc.2024.1511583.
[33]	Bridgewater J, Fletcher P, Palmer DH, et al. Long-term outcomes and exploratory analyses of the randomized phase Ⅲ BILCAP study[J]. J Clin Oncol, 2022, 40(18): 2048-2057.DOI: 10.1200/jco.21.02568.
[34]	Nakachi K, Ikeda M, Konishi M, et al. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial[J]. Lancet, 2023, 401(10372): 195-203.DOI: 10.1016/s0140-6736(22)02038-4.
[35]	Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase Ⅲ study[J]. J Clin Oncol, 2019, 37(8): 658-667.DOI: 10.1200/jco.18.00050.
[36]	Agrawal S, Kapoor V, Rahul R, et al. A randomized study of consolidation chemoradiotherapy versus observation after first-line chemotherapy in advanced gallbladder cancers: RACE-GB study[J]. Int J Radiat Oncol, 2025, 122(1): 10-18.DOI: 10.1016/j.ijrobp.2024.11.099.
[37]	Xiao H, Ji J, Li S, et al. Adjuvant chemoradiation and immunotherapy for extrahepatic cholangiocarcinoma and gallbladder cancer: a randomized clinical trial[J]. JAMA Oncol, 2025, 11(9): 1021.DOI: 10.1001/jamaoncol.2025.1926.
[38]	Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14): 1273-1281.DOI: 10.1056/nejmoa0908721.
[39]	Kim ST, Kang JH, Lee J, et al. Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase Ⅲ, noninferiority trial[J]. Ann Oncol, 2019, 30(5): 788-795.DOI: 10.1093/annonc/mdz058.
[40]	Morizane C, Okusaka T, Mizusawa J, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase Ⅲ clinical trial[J]. Ann Oncol, 2019, 30(12): 1950–1958.DOI: 10.1093/annonc/mdz402.
[41]	Shroff RT, King G, Colby S, et al. SWOG S1815: a phase Ⅲ randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers[J]. J Clin Oncol, 2025, 43(5): 536-544.DOI: 10.1200/jco-24-01383.
[42]	Ioka T, Kanai M, Kobayashi S, et al. Randomized phase Ⅲ study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401-MITSUBA)[J]. J Hepatobiliary Pancreat Sci, 2023, 30(1): 102-110.DOI: 10.1002/jhbp.1219.
[43]	Lamarca A, Palmer DH, Wasan HS, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial[J]. Lancet Oncol, 2021, 22(5): 690-701.DOI: 10.1016/s1470-2045(21)00027-9.
[44]	Yoo C, Kim KP, Jeong JH, et al. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study[J]. Lancet Oncol, 2021, 22(11): 1560-1572.DOI: 10.1016/s1470-2045(21)00486-1.
[45]	Vogel A, Saborowski A, Wenzel P, et al. Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2024, 9(8): 734-744.DOI: 10.1016/s2468-1253(24)00119-5.
[46]	Ramaswamy A, Ostwal V, Sharma A, et al. Efficacy of capecitabine plus irinotecan vs irinotecan monotherapy as second-line treatment in patients with advanced gallbladder cancer: a multicenter phase 2 randomized clinical trial (GB-SELECT)[J]. JAMA Oncol, 2021, 7(3): 436.DOI: 10.1001/jamaoncol.2020.6166.
[47]	Yoshikawa D, Ojima H, Iwasaki M, et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma[J]. Br J Cancer, 2008, 98(2): 418-425.DOI: 10.1038/sj.bjc.6604129.
[48]	Demols A, Borbath I, Van den Eynde M, et al. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase Ⅱ trial[J]. Ann Oncol, 2020, 31(9): 1169-1177.DOI: 10.1016/j.annonc.2020.05.018.
[49]	Ueno M, Ikeda M, Sasaki T, et al. Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results[J]. BMC Cancer, 2020, 20(1): 1105.DOI: 10.1186/s12885-020-07365-4.
[50]	Xu J, Bai Y, Sun H, et al. A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer[J]. Cancer, 2021, 127(21): 3975-3984.DOI: 10.1002/cncr.33803.
[51]	Okano N, Furuse J, Ueno M, et al. Multicenter phase Ⅱ trial of axitinib monotherapy for gemcitabine-based chemotherapy refractory advanced biliary tract cancer (AX-BC study)[J]. Oncologist, 2021, 26(2): 97-e201.DOI: 10.1002/onco.13547.
[52]	Galdy S, Lamarca A, McNamara MG, et al. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target[J]. Cancer Metastasis Rev, 2017, 36(1): 141-157.DOI: 10.1007/s10555-016-9645-x.
[53]	Javle MM, Oh DY, Ikeda M, et al. Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase Ⅱ study (TreeTopp)[J]. ESMO Open, 2022, 7(1): 100314.DOI: 10.1016/j.esmoop.2021.100314.
[54]	Lee CK, Chon HJ, Cheon J, et al. Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14)[J]. Lancet Gastroenterol Hepatol, 2023, 8(1): 56-65.DOI: 10.1016/s2468-1253(22)00335-1.
[55]	Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2023, 401(10391): 1853-1865.DOI: 10.1016/S0140-6736(23)00727-4.
[56]	Oh DY, He AR, Qin S, et al. Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase Ⅲ TOPAZ-1 study[J]. J Hepatol, 2025, 83(5): 1092-1101.DOI: 10.1016/j.jhep.2025.05.003.
[57]	Shi G, Huang X, Li X, et al. Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study[J]. Lancet Oncol, 2025, 26(10): 1334-1345.DOI: 10.1016/s1470-2045(25)00376-6.
[58]	Klein O, Kee D, Nagrial A, et al. Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: subgroup analysis of a phase 2 nonrandomized clinical trial[J]. JAMA Oncol, 2020, 6(9): 1405.DOI: 10.1001/jamaoncol.2020.2814.
[59]	Kim RD, Chung V, Alese OB, et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer[J]. JAMA Oncol, 2020, 6(6): 888.DOI: 10.1001/jamaoncol.2020.0930.

Please choose a citation manager

Content to export